Current Liabilities decreased faster than Fulgent Genetics Inc 's Cash & cash equivalent, this led to improvement in Fulgent Genetics Inc 's Quick Ratio to 3.58, Quick Ratio remained below Fulgent Genetics Inc average.

Within Medical Laboratories industry 11 other companies have achieved higher Quick Ratio than Fulgent Genetics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 105 to 876.

Explain Quick Ratio?
How much Cash & cash equivalents FLGT�s has?
What are FLGT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

FLGT Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	0.59 %	36.74 %	16.55 %	-2.11 %	-5.83 %
Y / Y Cash & cash equivalent Change	192.48 %	310.67 %	509.45 %	102.68 %	34.97 %
Quick Ratio MRQ	3.58	3.07	3.96	1.62	1.23
FLGT's Total Ranking	# 876	# 105	# 507	# 1182	# 1305
Seq. Current Liabilities Change	-20.39 %	6.08 %	17.32 %	1.53 %	8.22 %
Seq. Cash & cash equivalent Change	-6.97 %	-17.79 %	185.68 %	33.87 %	30.62 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 12
Healthcare Sector	# 366
Overall Market	# 876

Quick Ratio Statistics
High	Average	Low
14.46	4.33	0.71
(Sep 30 2018)		(Dec 31 2015)

Financial Statements
Fulgent Genetics Inc 's Current Liabilities	$ 72 Millions	Visit FLGT's Balance sheet
Fulgent Genetics Inc 's Cash & cash equivalent	$ 257 Millions	Visit FLGT's Balance sheet
Source of FLGT's Sales		Visit FLGT's Sales by Geography

Cumulative Fulgent Genetics Inc 's Quick Ratio

FLGT's Quick Ratio for the trailling 12 Months

FLGT Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	12.37 %	10.5 %	-1.32 %	-5.4 %	-0.7 %
Y / Y Cash & cash equivalent TTM Growth	267.83 %	233.05 %	161.35 %	19.12 %	-10.95 %
Quick Ratio TTM	3.09	2.57	2.07	1.16	0.94
Total Ranking TTM	# 3803	# 675	# 2382	# 2904	# 1164
Seq. Current Liabilities TTM Growth	0.13 %	8.22 %	4.27 %	-0.55 %	-1.53 %
Seq. Cash & cash equivalent TTM Growth	20.68 %	34.33 %	85.66 %	22.21 %	9.27 %

Quick ratio ranking by company, industry and sector >> Back to FLGT Financial Strength Comparisons >> Go to Compare FLGT Quick Ratio to its Competitors

On the trailing twelve months basis FLGT Cash & cash equivalent more than doubled by 192.48 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Fulgent Genetics Inc 's Quick Ratio to 3.09, Quick Ratio remained below FLGT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 34 other companies have achieved higher Quick Ratio than Fulgent Genetics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 675 to 3803.

Explain Quick Ratio?
How much Cash & cash equivalents FLGT�s has?
What are FLGT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 35
Healthcare Sector	# 875
Within the Market	# 3803

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.82	4.11	0.78
(Dec 31 2018)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Laboratories Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Billiontoone Inc	9.85	$ 548.628 Millions	$ 55.725 Millions
Celcuity Inc	8.68	$ 754.000 Millions	$ 86.873 Millions
Veracyte Inc	7.76	$ 487.046 Millions	$ 62.736 Millions
Personalis Inc	6.00	$ 278.411 Millions	$ 46.385 Millions
Castle Biosciences Inc	4.72	$ 266.805 Millions	$ 56.509 Millions
Bionexus Gene Lab Corp	4.33	$ 3.522 Millions	$ 0.813 Millions
Caredx Inc	3.99	$ 373.636 Millions	$ 93.698 Millions
Omniab Inc	3.78	$ 51.995 Millions	$ 13.758 Millions
Fulgent Genetics Inc	3.58	$ 257.032 Millions	$ 71.756 Millions
Guardant Health Inc	3.11	$ 1,053.469 Millions	$ 338.962 Millions
Butterfly Network Inc	2.13	$ 124.659 Millions	$ 58.603 Millions
Natera Inc	1.97	$ 1,091.502 Millions	$ 553.200 Millions
Biodesix Inc	1.96	$ 29.996 Millions	$ 15.291 Millions
Sera Prognostics Inc	1.91	$ 46.445 Millions	$ 24.356 Millions
Exagen Inc	1.83	$ 24.588 Millions	$ 13.457 Millions
Radnet Inc	1.11	$ 773.510 Millions	$ 697.822 Millions
Bioaffinity Technologies Inc	0.91	$ 2.430 Millions	$ 2.681 Millions

Date modified: 2026-09-14T03:53:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.